

NeuroScientific
BIOPHARMACEUTICALS

Suite 5, 85 Forrest St
Cottesloe WA 6011 Australia

11 November 2021

Chairman's 2021 Annual General meeting Address

Good morning ladies and gentlemen. Welcome to the 2021 AGM for NeuroScientific Biopharmaceuticals Limited. My name is Paul Rennie, the Chairman of NeuroScientific. I will also Chair today's meeting. Thank you for taking the time to attend this morning.

Given the significant health concerns attributed to the COVID-19 pandemic, in addition to guidelines and restrictions issued by Australian state and federal governments, the Company considers that it is appropriate to hold the 2021 AGM as a virtual meeting, in a manner that is consistent with the temporary modifications to the Corporations Act 2001 (Cth) introduced by the Commonwealth Treasurer.

It is now 10.00am and there being a quorum present, I declare the meeting open for business. I confirm that the meeting has been properly constituted.

In opening the 2021 AGM I would like to introduce you to your Board of Directors: Dr Anton Uvarov, Mr Stephen Quantrill and Mr Matt Liddelow. Members of the Board standing for re-election today are: Mr Stephen Quantrill and myself.

I would also like to introduce the CFO & Company Secretary Ms Abby Macnish.


Lastly, I would note that we have received an apology from Mr Stephen Quantrill, as last minute travel issues have resulted in him being unable to attend this AGM.

As this meeting is being conducted as a virtual meeting, I would like to welcome those shareholders that are joining us via zoom and ask that you please submit any questions or comments via the Q&A function which can be found at the bottom of your zoom screen. When you submit a question or comment please start by typing which resolution it relates to so that it can be addressed at the appropriate time.

Please start your question by typing your shareholding SRN or HIN. This will allow the moderator to identify you as a shareholder. If you would like to ask your question verbally, type your SRN or HIN and then type "I'd like to speak".

Once you have finished typing, please hit enter on your keyboard to send. When you submit a question or comment please start by typing which resolution it relates to so that it can be addressed at the appropriate time.

Questions which relate to the general business of the Company will be collected and addressed after the close of the formal business of the meeting.



NeuroScientific
BIOPHARMACEUTICALS

I will make a few comments on this exciting year of progress for NeuroScientific before introducing our Managing Director and Chief Executive Officer who will provide his report to you. I will then proceed with the formal aspects of this AGM as set out in the Notice of Annual General Meeting. We will then be happy to take any questions from Shareholders in attendance today.

The Company continued to significantly progress its research and development programs throughout the last 12-months and is highly focused on achieving the major milestone of transitioning our lead drug candidate EmtinB into its first Phase I clinical study.


Our Neurology non-clinical safety program is in the final stages of completion and the Company looks forward to finally transitioning the program into clinical development in the first quarter of 2022. This year we partnered with Linear Clinical Research, a leading Australian CRO, to start preparation for a first-in-human Phase I study of EmtinB that will recruit up to 90 patients across multiple doses. Throughout 2021 the company has participated in several industry partnering conferences, with NeuroScientific always attracting a lot of interest from big pharma, and the results of our Phase I study will be highly anticipated by these parties as well as our current research partners. Successful completion of the Phase I program will allow the company to initiate Phase II programs in Multiple Sclerosis, Alzheimer's and other neurodegenerative conditions. We intend to start preparing for our Phase II program during the next year while completing our Phase I study.

During the past 12 months we also achieved significant outcomes in our Multiple Sclerosis R&D program, creating a lot of attention at the industry conferences that I mentioned above. Most notably EmtinB reduced all major inflammatory markers associated with the disease, building upon an already impressive data set that positions EmtinB as a therapeutic with disease modifying potential for MS patients. To expand on that we recently partnered with leading Contract Research Organisation Biospective to conduct some pivotal animal studies using most innovative imaging techniques available that can put us at the forefront of MS research.

I'm also proud to say that this year our ophthalmology pre-clinical program completed a number of pivotal safety studies with 3 months non-human primate studies on track to be finalised in the early part of 2022 and allowing us to progress our Glaucoma program into Phase I.

I also want to highlight the dedicated work of our investor relations and corporate teams for preparing and participating in multiple retail investor conferences this year. Several virtual company presentations were made including at Gold Coast Investment Showcase, BIO Europe 2021, Ausbiotech Invest and South-West Connect. The company's options were listed for trade in October 2020 and due to the strong share price performance in the beginning of this calendar year, significant funds have been raised through the exercise of options which will allow us to compete both Phase I programs.

Before I pass over to Matt Liddelow, our CEO and Managing Director, I would like to take a moment to thank all our shareholders, for their continued support on this exciting journey allowing us to develop this novel disease modifying therapeutics. It has been a year full of surprises and problem solving for our team with so many components of our business affected by COVID related issues. However, I'm proud to say that the team handled all difficulties with utmost dedication, and we remain in a great position to move forward and to progress EmtinB into first-in-human clinical studies in just few months. Also, I would like to thank all our partners who are so crucial to the process and our ultimate success and who also despite




NeuroScientific
BIOPHARMACEUTICALS

COVID challenges worldwide remained focused on competing our IND enabling studies and helping us in bringing the Company to this point.

I would now like to invite Matt Liddelow to address the meeting.


Managing Director and CEO's 2021 Annual General Meeting Address

An illustration on a dark blue background shows a white silhouette of a person climbing a vertical rope on the left. A large, bright yellow spotlight beam emanates from the person, illuminating a large, detailed neuron in the center. The neuron has a yellow cell body with internal structures and several dark grey dendrites extending outwards. Other smaller, faint neuron silhouettes are scattered in the background.

**NOVEL DRUG
THERAPIES FOR
NEURODEGENERATIVE
CONDITIONS**


AGM PRESENTATION

MATT LIDDELOW: CEO & MD
11 NOVEMBER 2021



NeuroScientific

BIOPHARMACEUTICALS



NeuroScientific
BIOPHARMACEUTICALS

DISCLAIMER

The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Further information is available upon request.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside NeuroScientific’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and NeuroScientific’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by NeuroScientific. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

2021 IN REVIEW

>20
STUDIES
COMPLETED
IN 2021

CYQ1
2021

93% OF NSBO EXERCISED

Increased cash position

POSITIVE OCULAR PK & TISSUE DISTRIBUTION

Significant data to support monthly dosing of EmtinB™

CYQ2
2021

COMPLETED ASCENDING DOSE TOXICITY

Successfully completed in 2 species for neurology program

COMPLETED 4-WEEK OCULAR TOLERANCE & SAFETY

Weekly dose intervals did not cause any adverse events

CYQ3
2021

PARTNERED WITH LINEAR CLINICAL FOR PHASE I

Agreement to undertake Phase I clinical study for neurology program

POSITIVE OUTCOMES IN PULMONARY FIBROSIS STUDY

EmtinB™ significantly reduced inflammatory biomarkers associated with severe COVID-19


POSITIVE RESULTS IN MS BIOMARKER STUDY

EmtinB™ significantly reduced inflammatory biomarkers

CYQ4
2021

COMPLETED GLP SAFETY PHARMACOLOGY PROGRAM

CNS, respiratory, and cardiovascular




CORPORATE OVERVIEW

KEY FINANCIAL INFORMATION

ASX CODE	NSB
SHARES ON ISSUE	143M
SHARE PRICE¹	\$0.335
MARKET² CAPITALISATION	\$47M
UNLISTED OPTIONS	8.85M
NET CASH	\$12.3M
52 WEEK PRICE RANGE	\$0.20 - \$0.54

SHARE PRICE PERFORMANCE



LEADERSHIP AND MANAGEMENT TEAM



PAUL RENNIE, MBM, MSTC
NON-EXECUTIVE CHAIRMAN

Founding and current CEO of Paradigm Biopharmaceuticals (ASX:PAR). Former COO and Executive VP New Product Development at Mesoblast Ltd (ASX:MSB).



MATT LIDDELOW, MPHARM
CEO + MANAGING DIRECTOR

14+ years experience commercialising medical devices and pharmaceuticals for multi-national companies including AstraZeneca



DR ANTON UVAROV, PHD MBA
EXECUTIVE DIR + CSO

Founding director of Actinogen Medical (ASX:ACW) an advanced Alzheimer's biotechnology company. Former Equities Analyst with Citigroup, US



STEPHEN QUANTRILL, MBA
NON-EXECUTIVE DIRECTOR

20 years' experience in corporate advisory and company directorship, Executive Chairman of McRae Investments



ABBY MACNISH NIVEN, CFA
COMPANY SECRETARY + CFO



DOUGAL THRING, MPHARMED
VP CLINICAL DEVELOPMENT



DR ALEXANDRA ANDREWS, PHD
DIRECTOR OF OPERATIONS

COMPANY SNAPSHOT

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) is developing a peptide therapeutic with broad application in neurodegeneration



NOVEL LEAD COMPOUND

- EmtinB™ - potential first in-class therapeutic for neurodegenerative conditions
- Potential disease modifying therapeutic
- Low potential for off-target effects

SUBSTANTIAL SAFETY & EFFICACY DATA

- >40 studies completed to date
- Preclinical validation in models of Alzheimer's disease, Multiple sclerosis, Glaucoma, and Spinal Cord Injury
- Biomarker data for inflammation and immune processes

ADDRESSING UNMET NEED IN NEURODEGENERATION


- Alzheimer's disease – global prevalence 44M, high unmet need
- Multiple sclerosis – US\$27 billion treatment market, unmet need for progressive MS
- Glaucoma – 76M global prevalence, 2nd lead cause of blindness

WELL-FUNDED FOR PHASE I PROGRAMS

- Plan to undertake two Phase I clinical studies in 2022 – FIH Phase I for neurology indications and FIP Phase I for glaucoma
- \$12.3M cash on hand



EMTINB™ – PIPELINE IN A PRODUCT



PARTNERSHIPS & COLLABORATIONS

NON-CLINICAL RESEARCH



CLINICAL RESEARCH



MANUFACTURING





NEUROLOGY R&D HIGHLIGHTS

Significant progress achieved across our Neurology R&D Program in 2021

15

NON-CLINICAL
STUDIES
COMPLETED IN 2021

5

PIVOTAL SAFETY
STUDIES
COMPLETED IN 2021

3

IMPORTANT
BIOMARKERS
IDENTIFIED FOR
EMTINB™

MS 

PARTNERED WITH
BIOSPECTIVE TO
ACCELERATE MS
PROGRAM



OPHTHALMOLOGY R&D HIGHLIGHTS

Continued to progress our Ocular Safety Program and characterise the activity of EmtinB™ in the eye

7

NON-CLINICAL
STUDIES
COMPLETED IN 2021

3

PIVOTAL SAFETY
STUDIES
COMPLETED IN 2021

0

ADVERSE EFFECTS
OR SIGNS OF
TOXICITY



PATHWAY TO PHASE I CLINICAL STUDY

First-in-human Phase I study to support neurology treatment indications

APPOINTMENT OF
CLINICAL RESEARCH
PARTNER

UPSCALE PROCESS &
MANUFACTURE GMP
EMTINB™

PK, BIOAVAILABILITY &
METABOLISM STUDIES

GLP SAFETY
PHARMACOLOGY
STUDIES

NON-GLP SAFETY
STUDIES IN 2
SPECIES

COMPLETED

GLP REPEAT DOSE TOXICITY
IN 2 SPECIES

**CURRENTLY BEING
COMPLETED**

REGULATORY
SUBMISSION

CYQ1 2022

START PHASE I
STUDY



SIGNIFICANT VALUE UPSIDE FOR NSB IN 2022 & BEYOND

TRANSITIONING FROM PRECLINICAL TO CLINICAL DEVELOPMENT

- FIH Phase I neurology study planned for CYQ1 2022
- FIP Phase I glaucoma study planned for CYQ2 2022

POTENTIAL OUT-LICENSING OPPORTUNITY

- EmtinB™ continues to attract interest from potential mid-to-large licensing partners

EXPANDING INDICATION PIPELINE

- Accelerating Multiple sclerosis R&D program
- Complete ocular artery occlusion program
- Continue exploratory R&D

FOR MORE INFORMATION:

Matt Liddelow

CEO & Managing Director

ml@neuroscientific.com

www.neuroscientific.com



NeuroScientific
BIOPHARMACEUTICALS

